Osimertinib was the first drug to be approved for adjuvant treatment after complete tumour resection in adults with stage IB to IIIA non-small cell lung cancer (NSCLC).
from News Medical Medical Research News Feed https://ift.tt/3uxHUJI https://ift.tt/eA8V8J
from TechCrunch https://ift.tt/2Y8UAKQ
Saturday, 2 October 2021
Home »
Tech
,
TechCrunch
» Osimertinib offers a hint of added benefit for NSCLC patients who have received adjuvant chemotherapy
0 comments:
Post a Comment